{"id":68074,"date":"2026-11-09T18:17:28","date_gmt":"2026-11-09T12:47:28","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=68074"},"modified":"2026-11-09T18:17:32","modified_gmt":"2026-11-09T12:47:32","slug":"interactive-cardiology-mcqs-31-coronary-artery-disease","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/","title":{"rendered":"Interactive Cardiology MCQs 31: Coronary Artery Disease"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<!-- Cardiology MCQs Part 31 (Full 25 Questions - Coronary Artery Disease) - WordPress Safe Custom HTML Block -->\n<script src=\"https:\/\/cdn.tailwindcss.com?plugins=forms,typography,aspect-ratio\"><\/script>\n<script>\n  tailwind.config = { corePlugins: { preflight: false } }\n<\/script>\n\n<div id=\"mcq31-quiz-wrapper\" class=\"font-sans bg-slate-950 text-slate-100 p-4 md:p-8 rounded-3xl max-w-4xl mx-auto shadow-2xl relative overflow-hidden my-8 border border-solid border-cyan-500\/20\" style=\"box-sizing: border-box;\">\n  \n  <div class=\"absolute top-0 left-0 w-full h-full pointer-events-none opacity-10 bg-[radial-gradient(ellipse_at_center,_var(--tw-gradient-stops))] from-cyan-500 via-blue-900 to-slate-950\"><\/div>\n  \n  <div class=\"relative text-center pb-6 border-b border-solid border-cyan-500\/25 mb-8\">\n    <div class=\"inline-block bg-gradient-to-r from-cyan-500 via-blue-600 to-indigo-600 text-white font-black text-xs md:text-sm px-4 py-1.5 rounded-full uppercase tracking-wider shadow-lg mb-3 animate-pulse\">\n      \u26a1 Advanced Cardiology Series &#8211; Part 31\n    <\/div>\n    <h1 class=\"text-3xl md:text-5xl font-extrabold tracking-tight text-transparent bg-clip-text bg-gradient-to-r from-cyan-300 via-blue-400 to-indigo-400 m-0\">\n      Interactive Cardiology MCQs #31\n    <\/h1>\n    <p class=\"text-sm md:text-lg text-slate-300 mt-2 max-w-2xl mx-auto font-medium\">\n      Post-Graduate Level Masterclass: Coronary Artery Disease\n    <\/p>\n  <\/div>\n\n  <div class=\"sticky top-4 z-40 bg-slate-900\/90 backdrop-blur-md border-2 border-solid border-cyan-500\/40 rounded-2xl p-4 mb-8 shadow-xl flex flex-wrap items-center justify-between gap-4\">\n    <div class=\"flex items-center gap-3\">\n      <div class=\"text-3xl\">\ud83e\udec0<\/div>\n      <div>\n        <div class=\"text-[10px] uppercase font-extrabold tracking-widest text-cyan-300\">Live Scoreboard<\/div>\n        <div class=\"text-lg md:text-2xl font-black text-blue-300 flex items-center gap-1\">\n          <span id=\"mcq31-correct-count\">0<\/span><span class=\"text-slate-500 text-sm md:text-lg\">\/ 25 Correct<\/span>\n        <\/div>\n      <\/div>\n    <\/div>\n    <div class=\"flex items-center gap-2 bg-slate-950\/80 px-4 py-2 rounded-xl border border-solid border-slate-800\">\n      <span class=\"text-xs font-bold text-slate-400 uppercase tracking-wider\">Progress:<\/span>\n      <div class=\"w-24 md:w-36 bg-slate-800 h-3 rounded-full overflow-hidden\">\n        <div id=\"mcq31-progress-bar\" class=\"bg-gradient-to-r from-cyan-500 to-blue-500 h-full w-0 transition-all duration-300 rounded-full\"><\/div>\n      <\/div>\n      <span class=\"text-xs font-bold text-blue-300\"><span id=\"mcq31-answered-count\">0<\/span>\/25<\/span>\n    <\/div>\n  <\/div>\n\n  <div class=\"space-y-8 relative\">\n\n    <!-- Q1 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q1<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          During invasive physiological assessment of an intermediate coronary lesion, what are the clinically validated diagnostic thresholds for FFR and iFR indicating hemodynamic significance?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A threshold of 0.75 was used historically, but modern guidelines use 0.80 for FFR.\">A) FFR less than or equal to 0.75; iFR less than or equal to 0.85.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Guidelines indicate revascularization for intermediate lesions when Fractional Flow Reserve (FFR) is less than or equal to 0.80 (hyperemic) or Instantaneous Wave-Free Ratio (iFR) is less than or equal to 0.89 (resting). Reference: ESC\/EACTS Guidelines on Myocardial Revascularization.\">B) FFR less than or equal to 0.80; iFR less than or equal to 0.89.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"These values would lead to significant over-stenting of non-ischemic lesions.\">C) FFR less than or equal to 0.85; iFR less than or equal to 0.93.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"FFR and iFR evaluate different phases of the cardiac cycle; their cutoffs are not identical.\">D) FFR less than or equal to 0.80; iFR less than or equal to 0.80.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q2 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q2<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Optical Coherence Tomography (OCT) offers significantly higher spatial resolution than Intravascular Ultrasound (IVUS). What is the primary technical limitation of OCT compared to IVUS?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"OCT has a spatial resolution of 10 to 15 micrometers, superior to IVUS.\">A) Lower axial resolution, making strut apposition difficult to evaluate.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"OCT utilizes near-infrared light, which cannot penetrate red blood cells. It requires rapid contrast injection to clear blood from the vessel, limiting its use in ostial left main lesions or patients with severe renal impairment. IVUS does not require contrast. Reference: EAPCI Consensus on Intravascular Imaging.\">B) Requires clearing of red blood cells via contrast injection, limiting use in renal impairment.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"OCT penetrates calcium better than IVUS; ultrasound causes acoustic shadowing behind calcium.\">C) Cannot penetrate calcium sheets, producing deep acoustic shadows.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"OCT acquisition is extremely fast, usually taking under 5 seconds per pullback without pacing.\">D) Requires sustained rapid ventricular pacing to prevent motion artifact.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q3 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q3<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          The landmark ISCHEMIA trial evaluated patients with stable coronary artery disease and moderate-to-severe ischemia. What was its primary conclusion regarding an initial invasive strategy versus conservative medical therapy?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Invasive therapy did not reduce hard endpoints like overall mortality compared to optimal medical therapy.\">A) Invasive therapy significantly reduced 5-year all-cause mortality.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The ISCHEMIA trial demonstrated that an initial invasive strategy (PCI\/CABG) did not reduce the primary composite endpoint of CV death or MI compared to a conservative strategy. However, it provided significantly superior, durable relief of angina symptoms and improved quality of life. Reference: ISCHEMIA Trial (NEJM 2020).\">B) Invasive therapy did not reduce overall CV events or death, but provided superior relief of angina.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Patients with unprotected left main stenosis greater than 50 percent were explicitly excluded from the trial.\">C) Medical therapy was superior even in patients with unprotected left main stem disease.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While periprocedural MIs were higher early, spontaneous MIs were lower late; overall events were neutral.\">D) Invasive therapy increased late spontaneous myocardial infarctions due to stent failure.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q4 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q4<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In a hemodynamically stable STEMI patient presenting with multivessel CAD, what is the recommended strategy for non-culprit lesions based on the COMPLETE trial?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Culprit-only PCI resulted in significantly higher rates of re-infarction compared to complete revascularization.\">A) Culprit-only PCI should be performed; non-culprit lesions managed medically.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The COMPLETE trial established that in stable STEMI patients with multivessel disease, complete revascularization of all angiographically significant non-culprit lesions (during index admission or staged within 45 days) significantly reduced the composite of CV death or MI compared to culprit-only PCI. Reference: COMPLETE Trial (NEJM 2019).\">B) Complete revascularization of all significant non-culprit lesions during or after the index hospitalization.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Emergency CABG during an acute STEMI carries high mortality and is reserved for complex anatomy unsuitable for PCI.\">C) Immediate emergency CABG for all non-culprit lesions during the index intervention.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"FFR was not mandatory in COMPLETE, which randomized based on angiographic severity (greater than 70 percent stenosis).\">D) Non-culprit lesions should only be intervened upon if FFR is less than 0.70.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q5 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q5<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Based on the SYNTAX, EXCEL, and NOBLE trials, in patients with unprotected Left Main Coronary Artery (LMCA) disease, CABG remains superior to PCI in which specific patient population?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"PCI is highly acceptable and non-inferior to CABG in patients with low SYNTAX scores.\">A) Patients with low anatomical complexity (SYNTAX score less than 22).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In patients with Left Main disease and high anatomical complexity (SYNTAX score greater than or equal to 33, indicating diffuse, heavily calcified, or complex bifurcation disease), CABG provides a significant survival and freedom-from-revascularization benefit over PCI. PCI is a reasonable alternative for low or intermediate complexity. Reference: ESC\/EACTS Guidelines on Myocardial Revascularization.\">B) Patients with high anatomical complexity (SYNTAX score greater than or equal to 33).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Advanced age favors less invasive approaches like PCI, though CABG can be done if operative risk is acceptable.\">C) Patients older than 85 years regardless of anatomy.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Isolated ostial left main disease is structurally simple (low SYNTAX score) and highly suitable for PCI.\">D) Patients with isolated, discrete ostial left main stenosis.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q6 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q6<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          On Optical Coherence Tomography (OCT), what is the hallmark morphological feature of a &#8216;vulnerable plaque&#8217; most likely to cause an acute coronary syndrome?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Heavy, concentric calcification indicates a stable, chronic plaque, not a vulnerable, rupture-prone plaque.\">A) A thick, heavily calcified fibrous cap over a small lipid core.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The Thin-Cap Fibroatheroma (TCFA) is the classic precursor to plaque rupture and acute MI. On OCT, it is defined as a large, necrotic lipid core covered by an extremely thin fibrous cap measuring less than 65 micrometers in thickness. Reference: EAPCI Expert Consensus on OCT.\">B) A Thin-Cap Fibroatheroma (TCFA) with a fibrous cap thickness less than 65 micrometers.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Erosion can cause ACS, but the classic high-risk 'vulnerable' plaque refers to TCFA with a large necrotic core, not purely fibrous tissue.\">C) A homogeneous, fibrous plaque without any underlying lipid accumulation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A true aneurysm is a vessel wall dilation, not a vulnerable atherosclerotic plaque characteristic.\">D) An intact tunica media with outward aneurysmal remodeling.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q7 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q7<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A 40-year-old female presents with an NSTEMI. Angiography reveals Spontaneous Coronary Artery Dissection (SCAD) in the mid-LAD with TIMI 3 flow. She is hemodynamically stable and pain-free. What is the most appropriate management?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Routine stenting in SCAD is highly hazardous as the wire or stent can propagate the hematoma and cause total vessel occlusion.\">A) Immediate placement of a drug-eluting stent to seal the dissection flap.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"For hemodynamically stable patients with SCAD and preserved coronary flow (TIMI 2-3), conservative medical management is the standard of care. The vast majority of SCAD lesions heal spontaneously over weeks to months. PCI is reserved for ongoing ischemia, hemodynamic instability, or left main involvement, due to the high risk of extending the intramural hematoma. Reference: AHA Scientific Statement on SCAD.\">B) Conservative medical therapy and prolonged clinical observation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Fibrinolytics (thrombolytics) are strictly contraindicated in SCAD as they can drastically worsen the intramural bleeding.\">C) Administration of systemic fibrinolytics to dissolve the intramural hematoma.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"CABG is reserved for complex, multivessel, or left main SCAD with hemodynamic collapse, not stable mid-vessel disease.\">D) Emergency Coronary Artery Bypass Grafting (CABG).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q8 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q8<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          The diagnosis of MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries) requires universal criteria for acute MI, but specifically mandates that coronary angiography shows no stenosis greater than or equal to what percentage?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A 70 percent threshold defines severe CAD, but MINOCA uses a stricter threshold for 'non-obstructive'.\">A) 70 percent.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"MINOCA is a working diagnosis defined by the universal criteria for acute MI (biomarker rise\/fall with ischemia) coupled with coronary angiography showing non-obstructive disease, strictly defined as no epicardial stenosis greater than or equal to 50 percent in any infarct-related artery. Reference: ESC Guidelines on the Management of Acute Coronary Syndromes.\">B) 50 percent.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A 30 percent stenosis is non-obstructive, but the official definition sets the cap at less than 50 percent.\">C) 30 percent.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Zero percent implies totally pristine arteries, but MINOCA allows for mild atherosclerosis (up to 49 percent).\">D) 0 percent (perfectly normal coronary arteries only).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q9 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q9<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In a patient diagnosed with Vasospastic (Prinzmetal) Angina, which class of medications is strictly contraindicated because it can exacerbate coronary vasospasm by leaving alpha-receptors unopposed?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Calcium Channel Blockers are the first-line therapy of choice for vasospastic angina as they directly prevent smooth muscle contraction.\">A) Non-dihydropyridine Calcium Channel Blockers.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Non-selective Beta-blockers (like propranolol) are contraindicated in pure vasospastic angina. Blocking beta-2 vasodilatory receptors leaves alpha-1 vasoconstrictor receptors unopposed, which can precipitate or severely worsen coronary artery spasm. Calcium channel blockers and nitrates are the treatments of choice. Reference: ACC\/AHA Guidelines for Stable Ischemic Heart Disease.\">B) Non-selective Beta-blockers.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Nitrates are potent vasodilators and are routinely used to relieve acute episodes of vasospasm.\">C) Long-acting Nitrates.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Statins improve endothelial function and are safe and recommended for these patients.\">D) HMG-CoA reductase inhibitors (Statins).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q10 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q10<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          According to current ESC guidelines, what is the default recommended duration of Dual Antiplatelet Therapy (DAPT) for a patient with Chronic Coronary Syndrome (stable angina) who undergoes elective PCI with a Drug-Eluting Stent (DES) and has standard bleeding risk?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"1 month is reserved for patients with very high bleeding risk (HBR).\">A) 1 month.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"For patients with Chronic Coronary Syndrome (stable CAD) undergoing elective PCI with a modern DES and possessing a standard bleeding risk, the default guideline-recommended duration for DAPT (Aspirin + Clopidogrel) is 6 months. After 6 months, single antiplatelet therapy (SAPT) is continued indefinitely. Reference: ESC Guidelines on Dual Antiplatelet Therapy.\">B) 6 months.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"12 months is the default duration for Acute Coronary Syndromes (ACS), not stable CAD.\">C) 12 months.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Indefinite DAPT is not recommended due to unacceptably high cumulative bleeding risks.\">D) Indefinitely.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q11 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q11<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient presenting with a STEMI undergoes successful primary PCI. What is the standard guideline-recommended duration of Dual Antiplatelet Therapy (DAPT) post-procedure, assuming no high bleeding risk?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"3 months is an abbreviated strategy for very high bleeding risk, not the default for standard risk ACS.\">A) 3 months.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"6 months is the standard for stable elective PCI, not ACS.\">B) 6 months.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Regardless of the stent type used, all patients presenting with an Acute Coronary Syndrome (STEMI or NSTEMI) who are not at high bleeding risk should receive a default of 12 months of DAPT. A potent P2Y12 inhibitor (Ticagrelor or Prasugrel) is preferred over Clopidogrel. Reference: ESC\/AHA Guidelines for the Management of Acute Coronary Syndromes.\">C) 12 months.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"36 months is an extended therapy (PEGASUS-TIMI 54) for highly selected patients, not the default standard.\">D) 36 months.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q12 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q12<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Ticagrelor is a potent antiplatelet agent used in ACS. How does its pharmacological mechanism differ from that of Clopidogrel and Prasugrel?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Ticagrelor requires twice-daily dosing (BID) because it is a reversible inhibitor, whereas clopidogrel\/prasugrel are once-daily.\">A) Ticagrelor is an irreversible prodrug requiring once-daily dosing.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Unlike Clopidogrel and Prasugrel (which are thienopyridine prodrugs that irreversibly bind to the P2Y12 receptor), Ticagrelor is a cyclopentyltriazolopyrimidine (CPTP). It is an active drug (not a prodrug) that binds directly and REVERSIBLY to the P2Y12 receptor. Because it is reversible, platelet function recovers faster once stopped, but it requires twice-daily dosing. Reference: PLATO Trial.\">B) Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Glycoprotein IIb\/IIIa inhibitors include abciximab and tirofiban, not ticagrelor.\">C) Ticagrelor is an intravenous Glycoprotein IIb\/IIIa inhibitor.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Aspirin irreversibly inhibits COX-1; ticagrelor targets the P2Y12 ADP receptor.\">D) Ticagrelor irreversibly inhibits the Cyclooxygenase-1 (COX-1) enzyme.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q13 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q13<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Prasugrel is a highly potent P2Y12 inhibitor. According to the TRITON-TIMI 38 trial, in which patient population is Prasugrel strictly contraindicated due to an unacceptably high risk of fatal intracranial hemorrhage?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The TRITON-TIMI 38 trial showed that Prasugrel is strictly contraindicated in patients with any prior history of Stroke or Transient Ischemic Attack (TIA), as it causes a significant increase in fatal intracranial hemorrhage in this group. It is also generally avoided or dose-reduced in patients over 75 years old or weighing less than 60 kg. Reference: TRITON-TIMI 38 Trial.\">A) Patients with a prior history of Stroke or Transient Ischemic Attack (TIA).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Prior GI bleed requires caution and PPI therapy, but prior stroke\/TIA is the absolute black-box contraindication.\">B) Patients with a history of peptic ulcer disease.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Diabetics actually derive significant ischemic benefit from prasugrel compared to clopidogrel.\">C) Patients with uncontrolled Diabetes Mellitus.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Renal failure requires careful dosing, but is not the specific absolute contraindication identified in TRITON-TIMI 38.\">D) Patients with End-Stage Renal Disease on hemodialysis.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q14 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q14<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Stent thrombosis is a catastrophic complication. By standard ARC (Academic Research Consortium) definitions, &#8216;Late Stent Thrombosis&#8217; occurs within what specific timeframe following stent implantation?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Within 24 hours is defined as 'Acute' stent thrombosis.\">A) Within 24 hours.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Between 24 hours and 30 days is defined as 'Subacute' stent thrombosis.\">B) Between 24 hours and 30 days.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"According to ARC criteria, stent thrombosis is classified by timing: Acute (within 24 hours), Subacute (24 hours to 30 days), Late (30 days to 1 year), and Very Late (greater than 1 year). Late stent thrombosis is often related to delayed endothelialization or cessation of DAPT. Reference: Academic Research Consortium Stent Definitions.\">C) Between 30 days and 1 year.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Greater than 1 year is defined as 'Very Late' stent thrombosis.\">D) Greater than 1 year.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q15 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q15<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          An ECG reveals ST-segment elevation in leads II, III, and aVF. Which specific ECG finding strongly suggests that the Right Coronary Artery (RCA) is occluded PROXIMAL to the right ventricular branch, causing concurrent Right Ventricular infarction?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In an inferior STEMI, ST elevation in lead III greater than lead II implies an RCA occlusion (the vector points rightward). Furthermore, ST elevation in lead V1 (a right-sided lead) or ST depression in V2 greater than V1 strongly suggests right ventricular involvement, which occurs when the RCA is occluded proximally. Reference: ACC\/AHA STEMI Guidelines (ECG Localization).\">A) ST elevation in lead III greater than lead II, alongside ST elevation in V1.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"ST elevation in lead II greater than III, and elevation in I and aVL points to a left circumflex (LCx) occlusion.\">B) ST elevation in lead II greater than lead III, alongside ST elevation in I and aVL.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Deep ST depression in V1-V3 suggests a posterior STEMI, but does not specifically confirm proximal RV branch involvement.\">C) Deep, symmetrical T wave inversions in leads V1 through V3.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A new Left Bundle Branch Block (LBBB) obscures the anatomical localization on a standard 12-lead and usually involves the LAD.\">D) The presence of a new-onset Left Bundle Branch Block (LBBB).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q16 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q16<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Coronary dominance is anatomically determined by which artery supplies the Posterior Descending Artery (PDA) and the posterolateral branches. In approximately what percentage of the general population is the heart &#8216;Right Dominant&#8217;?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"10-15 percent is the rate for Left Dominance (PDA supplied by the Circumflex).\">A) 10 to 15 percent.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"50 percent underestimates right dominance.\">B) 50 percent.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In roughly 80 to 85 percent of the population, the heart is Right Dominant, meaning the Posterior Descending Artery (PDA) and posterolateral branches originate from the Right Coronary Artery (RCA). About 10 percent are Left Dominant (PDA from the Circumflex), and 5-10 percent are Co-Dominant. Reference: Standard Coronary Angiography Anatomy.\">C) 80 to 85 percent.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"99 percent implies almost universal uniformity, which is incorrect as left and co-dominance make up roughly 15-20 percent.\">D) 99 percent.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q17 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q17<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient is pain-free in the ER but their ECG demonstrates deep, symmetric, biphasic T wave inversions in leads V2 and V3 without significant Q waves or ST elevation. This is highly specific for Wellens&#8217; Syndrome. What does this pattern indicate?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A pulmonary embolism can cause T wave inversions in V1-V4, but Wellens' syndrome implies critical coronary ischemia.\">A) A massive acute pulmonary embolism causing right ventricular strain.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Wellens' Syndrome (or Wellens' Warning) is an ECG pattern characterized by biphasic or deeply inverted T waves in V2 and V3, recorded during a pain-free interval. It is highly specific for a critical, highly unstable stenosis of the proximal Left Anterior Descending (LAD) artery. If unrecognized and subjected to a stress test, it rapidly progresses to a massive anterior STEMI. Reference: Classic Electrocardiographic Syndromes.\">B) A critical, highly unstable stenosis of the proximal Left Anterior Descending (LAD) artery.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Circumflex occlusions typically affect the lateral (I, aVL, V5, V6) or posterior leads, not V2\/V3 biphasic T waves.\">C) An acute, complete thrombotic occlusion of the Left Circumflex artery.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Brugada syndrome presents with coved ST elevation in V1-V2, not deep biphasic T waves in a pain-free ACS patient.\">D) Congenital Brugada Syndrome Type 1.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q18 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q18<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Which ECG pattern is recognized as a &#8216;STEMI equivalent&#8217; indicating acute acute LAD occlusion, characterized by upsloping ST depression (greater than 1mm) at the J-point continuing into tall, positive, symmetrical hyperacute T waves in the precordial leads?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Wellens' features biphasic or inverted T waves in a pain-free state, not upsloping ST depression with hyperacute T waves during pain.\">A) Wellens&#8217; Syndrome.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The 'de Winter' ECG pattern is a critical STEMI equivalent occurring in roughly 2 percent of acute proximal LAD occlusions. Instead of classic ST elevation, the ECG shows 1-3 mm of upsloping ST-segment depression at the J-point in leads V1-V6, feeding directly into tall, prominent, symmetrical 'hyperacute' T waves. It requires immediate cath lab activation. Reference: ESC Guidelines for Acute Coronary Syndromes.\">B) de Winter Pattern.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Brugada pattern features coved ST elevation and negative T waves in V1-V2.\">C) Brugada Type 2 Pattern.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Osborn waves are J-point deflections seen in severe hypothermia.\">D) Osborn (J) Wave Pattern.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q19 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q19<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          During coronary angiography for suspected vasospastic angina, a provocation test is performed. Which two pharmacological agents are most commonly injected intracoronary to provoke spasm for diagnostic purposes?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Adenosine and Regadenoson are vasodilators used for FFR or stress testing; they do not provoke focal epicardial spasm.\">A) Adenosine and Regadenoson.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Ergonovine and Acetylcholine are the gold-standard provocative agents used in the cath lab to induce coronary vasospasm. A positive test is defined as greater than 90 percent focal vasoconstriction accompanied by ischemic ECG changes and reproduced chest pain. Nitroglycerin is given immediately after to reverse the spasm. Reference: ACC\/AHA Ischemic Heart Disease Guidelines.\">B) Ergonovine and Acetylcholine.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Nitroglycerin is a potent vasodilator used to REVERSE spasm, and Verapamil also prevents spasm.\">C) Nitroglycerin and Verapamil.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Dobutamine and Isoproterenol are positive inotropes\/chronotropes used to simulate exercise, not to induce direct focal epicardial spasm.\">D) Dobutamine and Isoproterenol.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q20 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q20<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Anomalous Aortic Origin of a Coronary Artery (AAOCA) is a rare congenital condition causing sudden cardiac death in young athletes. Which specific anatomical variant carries the highest &#8220;malignant&#8221; risk?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A retroaortic course is generally considered a benign variant.\">A) The RCA arising from the left sinus with a retroaortic course.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The most malignant variant of AAOCA occurs when a coronary artery (especially the Left Main) originates from the opposite sinus and takes an 'interarterial course'\u2014passing directly between the aorta and the pulmonary artery. During exercise, the expansion of the aorta and pulmonary artery acts like a scissor, physically compressing the anomalous vessel and causing fatal ischemia. Reference: AHA Congenital Heart Disease Guidelines.\">B) The Left Main arising from the right sinus and taking an interarterial course between the aorta and pulmonary artery.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"An anterior\/pre-pulmonic course is typically benign.\">C) The Left Main arising from the right sinus with an anterior course over the pulmonary artery.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A subpulmonic\/septal course is generally benign and protected from compression.\">D) The LAD arising from the right sinus with a septal (subpulmonic) course.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q21 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q21<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          According to the latest ESC Guidelines on Dyslipidaemias, what is the target LDL-C level for a patient at &#8216;very high cardiovascular risk&#8217; (e.g., secondary prevention post-MI)?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the target for high-risk, not very high-risk patients.\">A) Less than 70 mg\/dL (1.8 mmol\/L).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Current ESC guidelines have significantly lowered the target. For 'very high risk' patients (such as those with established CAD or recent ACS), the LDL-C goal is both a greater than or equal to 50 percent reduction from baseline AND an absolute level less than 55 mg\/dL (1.4 mmol\/L). Reference: ESC\/EAS Guidelines for the Management of Dyslipidaemias.\">B) Less than 55 mg\/dL (1.4 mmol\/L) and at least a 50 percent reduction from baseline.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is an outdated target for moderate risk.\">C) Less than 100 mg\/dL (2.6 mmol\/L).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While less than 40 mg\/dL is considered for patients with multiple events in two years, the standard very high-risk target is 55 mg\/dL.\">D) Less than 40 mg\/dL (1.0 mmol\/L) for all secondary prevention.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q22 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q22<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          PCSK9 inhibitors (e.g., Alirocumab, Evolocumab) drastically lower LDL-C levels. How exactly does PCSK9 inhibition achieve this effect at the cellular level?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes the mechanism of Ezetimibe, which works in the intestine.\">A) By blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestine.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"PCSK9 is an enzyme that binds to LDL receptors on hepatocytes, marking them for lysosomal degradation. By inhibiting PCSK9, the LDL receptors are not destroyed but rather recycled back to the liver cell surface. This exponentially increases the density of active LDL receptors, which clear circulating LDL-C from the blood. Reference: FOURIER and ODYSSEY OUTCOMES trials.\">B) By preventing the degradation of hepatic LDL receptors, allowing them to recycle to the cell surface and clear more LDL from the blood.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the mechanism of Statins (HMG-CoA reductase inhibitors).\">C) By competitively inhibiting HMG-CoA reductase, halting de novo cholesterol synthesis in the liver.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes the mechanism of Fibrates, which act on PPAR-alpha to lower triglycerides.\">D) By agonizing the PPAR-alpha receptor, increasing lipoprotein lipase activity.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q23 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q23<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          The REDUCE-IT trial demonstrated significant cardiovascular risk reduction using icosapent ethyl in statin-treated patients. What specific lipid abnormality must be present to qualify a patient for this therapy?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Icosapent ethyl primarily targets residual risk driven by triglycerides, not low HDL.\">A) Isolated low HDL cholesterol less than 35 mg\/dL.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The REDUCE-IT trial showed that in high-risk, statin-treated patients with elevated fasting triglycerides (135 to 499 mg\/dL), adding icosapent ethyl (highly purified EPA) significantly reduced cardiovascular events. It targets residual risk associated with triglyceride-rich lipoproteins. Reference: REDUCE-IT Trial (NEJM).\">B) Elevated fasting Triglycerides (135 to 499 mg\/dL) despite optimal statin therapy.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Elevated Lp(a) is an independent risk factor, but icosapent ethyl was not specifically studied or approved based on Lp(a) levels.\">C) Elevated Lipoprotein(a) greater than 50 mg\/dL.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Patients with LDL over 190 typically require PCSK9 inhibitors or ezetimibe; REDUCE-IT targeted triglycerides.\">D) Refractory LDL cholesterol greater than 190 mg\/dL.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q24 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q24<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          When assessing myocardial viability before CABG in a patient with severe ischemic cardiomyopathy, a Cardiac PET scan evaluates both perfusion and metabolism. What specific PET &#8216;mismatch&#8217; pattern indicates viable, hibernating myocardium that will benefit from revascularization?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Reduced perfusion and reduced metabolism defines a 'match', which indicates dead, scarred tissue (infarction).\">A) Reduced perfusion matched with proportionally reduced glucose metabolism.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Hibernating myocardium is chronically ischemic but alive. On a PET scan (using Rubidium-82\/Ammonia for perfusion and FDG for metabolism), it exhibits a 'perfusion-metabolism mismatch'. This means there is significantly reduced blood flow (perfusion) to the area, but preserved or increased glucose metabolism (as the hypoxic cells shift to anaerobic glycolysis). Revascularization of this tissue improves EF. Reference: ASNC Nuclear Cardiology Guidelines.\">B) Reduced perfusion but preserved or increased glucose metabolism.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Normal perfusion with reduced metabolism is not a classic pattern for ischemia; it may suggest artifact or non-ischemic cardiomyopathy.\">C) Normal resting perfusion with severely reduced glucose metabolism.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Normal perfusion and normal metabolism indicates healthy tissue, not hibernating tissue.\">D) Normal perfusion matched with normal glucose metabolism.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q25 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q25<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          During complex PCI, Rotational Atherectomy (e.g., Rotablator) is utilized. What is the primary angiographic and lesion characteristic that necessitates the use of rotational atherectomy prior to stenting?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Soft, lipid-rich vulnerable plaques can embolize during atherectomy; standard stenting with emboli protection is preferred.\">A) A soft, lipid-rich vulnerable plaque prone to distal embolization.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Rotational atherectomy utilizes a diamond-tipped burr spinning at up to 180,000 RPM. It exploits 'differential cutting', pulverizing hard, inelastic material while deflecting off healthy elastic tissue. It is strictly indicated for severely, circumferentially calcified, unyielding lesions that cannot be crossed or dilated by standard balloons, ensuring adequate stent expansion. Reference: ACC\/AHA Interventional Cardiology Guidelines.\">B) Severe, concentric, heavily calcified inelastic lesions that are un-crossable or un-dilatable by balloons.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Thrombus is a contraindication for atherectomy, as the burr will not cut it and it increases the risk of massive no-reflow. Aspiration thrombectomy is used.\">C) A massive, fresh red thrombus burden in the setting of an acute STEMI.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Atherectomy does not prevent vasospasm and would aggressively injure the vessel in Prinzmetal angina.\">D) Diffuse, severe coronary vasospasm resistant to intracoronary nitroglycerin.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n  <\/div>\n<\/div>\n\n<script>\n  let mcq31Correct = 0;\n  let mcq31Answered = 0;\n  const mcq31Total = 25;\n\n  document.querySelectorAll('#mcq31-quiz-wrapper .quiz-card').forEach(card => {\n    const buttons = card.querySelectorAll('.opt-btn');\n    buttons.forEach(btn => {\n      btn.addEventListener('click', function() {\n        if (card.getAttribute('data-answered') === 'true') return;\n        card.setAttribute('data-answered', 'true');\n        mcq31Answered++;\n\n        document.getElementById('mcq31-answered-count').innerText = mcq31Answered;\n        const pct = (mcq31Answered \/ mcq31Total) * 100;\n        document.getElementById('mcq31-progress-bar').style.width = pct + '%';\n\n        buttons.forEach(b => {\n          b.disabled = true;\n          b.classList.remove('hover:bg-slate-900', 'cursor-pointer');\n          b.classList.add('opacity-50', 'cursor-not-allowed');\n        });\n\n        const isCorrect = this.getAttribute('data-correct') === 'true';\n        const explanation = this.getAttribute('data-explanation');\n\n        if (isCorrect) {\n          mcq31Correct++;\n          document.getElementById('mcq31-correct-count').innerText = mcq31Correct;\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-teal-950\/80', 'border-teal-500', 'text-teal-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10004; CORRECT!<\/span>';\n        } else {\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-cyan-950\/80', 'border-blue-500', 'text-cyan-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10006; INCORRECT<\/span>';\n\n          buttons.forEach(b => {\n            if (b.getAttribute('data-correct') === 'true') {\n              b.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n              b.classList.add('bg-teal-950\/40', 'border-teal-500\/55', 'text-teal-200', 'opacity-100', 'border-2');\n              b.innerHTML += ' <span class=\"font-bold\">&#10004; (Correct)<\/span>';\n            }\n          });\n        }\n\n        const feedback = card.querySelector('.feedback-box');\n        feedback.innerHTML = `\n          <div class=\"font-extrabold uppercase tracking-widest text-xs mb-2 ${isCorrect ? 'text-teal-400' : 'text-cyan-400'}\">\n            ${isCorrect ? 'Clinical Explanation & Reference' : 'Explanation, Correct Answer & Reference'}\n          <\/div>\n          <p class=\"m-0\">${explanation}<\/p>\n        `;\n        feedback.classList.remove('hidden');\n        feedback.classList.add('block', isCorrect ? 'bg-teal-950\/45' : 'bg-cyan-950\/20', 'border-2', 'border-solid', isCorrect ? 'border-teal-500\/30' : 'border-blue-500\/30', 'text-slate-200', 'mt-4');\n      });\n    });\n  });\n<\/script>\n\n\n","protected":false},"excerpt":{"rendered":"<p>\u26a1 Advanced Cardiology Series &#8211; Part 31 Interactive Cardiology MCQs #31 Post-Graduate Level Masterclass: Coronary Artery Disease \ud83e\udec0 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 During invasive physiological assessment of an intermediate coronary lesion, what are the clinically validated diagnostic thresholds for FFR and iFR indicating hemodynamic significance? A) FFR less than or equal [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":68076,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","nfd_image_url":"","nfd_onboarding_generated":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-68074","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Interactive Cardiology MCQs 31: Coronary Artery Disease - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interactive Cardiology MCQs 31: Coronary Artery Disease - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"\u26a1 Advanced Cardiology Series &#8211; Part 31 Interactive Cardiology MCQs #31 Post-Graduate Level Masterclass: Coronary Artery Disease \ud83e\udec0 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 During invasive physiological assessment of an intermediate coronary lesion, what are the clinically validated diagnostic thresholds for FFR and iFR indicating hemodynamic significance? A) FFR less than or equal [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T12:47:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-09T12:47:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-31-Coronary-Artery-Disease.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1208\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Interactive Cardiology MCQs 31: Coronary Artery Disease\",\"datePublished\":\"2026-11-09T12:47:28+00:00\",\"dateModified\":\"2026-11-09T12:47:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/\"},\"wordCount\":1639,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-31-Coronary-Artery-Disease.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/\",\"name\":\"Interactive Cardiology MCQs 31: Coronary Artery Disease - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-31-Coronary-Artery-Disease.jpg\",\"datePublished\":\"2026-11-09T12:47:28+00:00\",\"dateModified\":\"2026-11-09T12:47:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-31-Coronary-Artery-Disease.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-31-Coronary-Artery-Disease.jpg\",\"width\":1208,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-31-coronary-artery-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interactive Cardiology MCQs 31: Coronary Artery Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interactive Cardiology MCQs 31: Coronary Artery Disease - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/","og_locale":"en_US","og_type":"article","og_title":"Interactive Cardiology MCQs 31: Coronary Artery Disease - All About Cardiovascular System and Disorders","og_description":"\u26a1 Advanced Cardiology Series &#8211; Part 31 Interactive Cardiology MCQs #31 Post-Graduate Level Masterclass: Coronary Artery Disease \ud83e\udec0 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 During invasive physiological assessment of an intermediate coronary lesion, what are the clinically validated diagnostic thresholds for FFR and iFR indicating hemodynamic significance? A) FFR less than or equal [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-11-09T12:47:28+00:00","article_modified_time":"2026-11-09T12:47:32+00:00","og_image":[{"width":1208,"height":675,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-31-Coronary-Artery-Disease.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Interactive Cardiology MCQs 31: Coronary Artery Disease","datePublished":"2026-11-09T12:47:28+00:00","dateModified":"2026-11-09T12:47:32+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/"},"wordCount":1639,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-31-Coronary-Artery-Disease.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/","url":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/","name":"Interactive Cardiology MCQs 31: Coronary Artery Disease - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-31-Coronary-Artery-Disease.jpg","datePublished":"2026-11-09T12:47:28+00:00","dateModified":"2026-11-09T12:47:32+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-31-Coronary-Artery-Disease.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-31-Coronary-Artery-Disease.jpg","width":1208,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-31-coronary-artery-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Interactive Cardiology MCQs 31: Coronary Artery Disease"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=68074"}],"version-history":[{"count":1,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68074\/revisions"}],"predecessor-version":[{"id":68075,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68074\/revisions\/68075"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/68076"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=68074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=68074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=68074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}